Cipla's Goa Plant Gets 2 USFDA Observations After cGMP, Pre-Approval Inspection
New Delhi: Cipla Limited has informed that the United States Food and Drug Administration (USFDA) conducted a routine current Good Manufacturing Practices (cGMP) inspection along with a Pre-Approval Inspection (PAI) at its manufacturing facility located in Verna, Goa, following which the company received two inspectional observations in Form 483.
The inspection was conducted from April 6 to April 17, 2026. The company has committed to address the observations within the stipulated timeline.
The inspection was carried out by the USFDA as part of its regulatory review processes, covering both compliance with cGMP standards and evaluation related to product approvals under the Pre-Approval Inspection framework.
At the conclusion of the inspection, the USFDA issued a Form 483 containing two observations, indicating specific areas where corrective actions are required. Cipla stated that it will work closely with the USFDA to comprehensively resolve the observations and ensure continued adherence to regulatory expectations.
The Goa facility, situated in Verna, remains an important part of the company’s manufacturing operations, supporting both domestic and international markets.
